ARIAD Pharma (ARIA) Updates on AP26113; Will Start at Lower Dose to Lessen Pulmonary Symptoms
Tweet Send to a Friend
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
